FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Manfred Schmitt

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Anatomy

Physiology

Gene Expression Regulation, Neoplastic

Co-author Network

Publications

TOP 3
Bettina Grismayer; Charlotte Kopitz; Matthias Kotzsch; Achim Krüger; Thomas Luther; Christian Ries; Sumito Sato; Manfred Schmitt; Susanne Soelch; Gustavo Baretton; Viktor Magdolen
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
Bettina Grismayer; Thomas Kirchner; Matthias Kotzsch; Achim Krüger; Thomas Luther; Sonja Schäfer; Manfred Schmitt; Bastian Seubert; Susanne Sölch; Gustavo Baretton; Viktor Magdolen
Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.
Holger Bronger; Claudia Cerny; Marion Kiechle; Sara Kraeft; Ulrike Schwarz-Boeger; Alexandra Stöckel; Stefanie Avril; Manfred Schmitt
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Manfred Schmitt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Bettina Grismayer; Charlotte Kopitz; Matthias Kotzsch; Achim Krüger; Thomas Luther; Christian Ries; Sumito Sato; Manfred Schmitt; Susanne Soelch; Gustavo Baretton; Viktor Magdolen
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
Biological chemistry 2012;393(12):1449-55.
2012: Bettina Grismayer; Thomas Kirchner; Matthias Kotzsch; Achim Krüger; Thomas Luther; Sonja Schäfer; Manfred Schmitt; Bastian Seubert; Susanne Sölch; Gustavo Baretton; Viktor Magdolen
Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.
Molecular cancer 2012;11():62.
2012: Holger Bronger; Claudia Cerny; Marion Kiechle; Sara Kraeft; Ulrike Schwarz-Boeger; Alexandra Stöckel; Stefanie Avril; Manfred Schmitt
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Breast cancer research : BCR 2012;14(1):R30.
2011: Andreas Kolk; M Kremer; Klaus Mantwill; Karin Mengele; Manfred Schmitt; O Bissinger; N Jubitz; Per Sonne Holm
Expression of Y-box-binding protein YB-1 allows stratification into long- and short-term survivors of head and neck cancer patients.
British journal of cancer 2011;105(12):1864-73.
2011: Matthias Kotzsch; Janna Krol; Barbara Schmalfeldt; Manfred Schmitt; Gustavo Baretton; Kristina Doetzer; Julia Dorn; Marion Kiechle; Viktor Magdolen
mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer.
Biological chemistry 2011;392(11):1047-51.
2011: Julia Dorn; T Gerte; A Gkazepis; Nadia Harbeck; Antonina Harlozinska; Marion Kiechle; Viktor Magdolen; T Schuster; Pawel Sedlaczek; Eleftherios P Diamandis; Manfred Schmitt
Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(8):1783-90.
2011: Manfred Schmitt; Nils Brünner; Julia Dorn; Nadia Harbeck; Fritz Jänicke; Heike Jansen; Eva J Kantelhardt; Christoph Meisner; Bernd Mühlenweg; Ulrike Nitz; Christoph Thomssen
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert review of molecular diagnostics 2011;11(6):617-34.
2011: Sumito Sato; Charlotte Kopitz; Bettina Grismayer; Nathalie Beaufort; Ute Reuning; Manfred Schmitt; Thomas Luther; Matthias Kotzsch; Achim Krüger; Viktor Magdolen
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Breast cancer research and treatment 2011;127(3):649-57.
2011: Johannes Schauwecker; Rüdiger von Eisenhart-Rothe; Rainer Burgkart; Jutta Tuebel; Manfred Schmitt; Wolfram Mittelmeier; Peter Diehl
Revitalization of human bone after extracorporeal high hydrostatic pressure treatment.
Anticancer research 2011;31(4):1235-9.
2011: Julia Dorn; Nadia Harbeck; Ronald Kates; A Gkazepis; Andreas Scorilas; A Soosaipillai; Eleftherios P Diamandis; Marion Kiechle; Barbara Schmalfeldt; Manfred Schmitt
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(4):877-83.
2011: Stephanie Hauser; Laura Bickel; Dirk Weinspach; Michael Gerg; Michael K Schäfer; Marco Pfeifer; John Hazin; Florian Schelter; Ulrich H Weidle; Juliane Ramser; Juliane Volkmann; Alfons Meindl; Manfred Schmitt; Florian Schrötzlmair; Peter Altevogt; Achim Krüger
Full-length L1CAM and not its Δ2Δ27 splice variant promotes metastasis through induction of gelatinase expression.
PloS one 2011;6(4):e18989.
2010: Karin Mengele; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Apostolos Gkazepis; Fred Sweep; Nils Brünner; John Foekens; Nadia Harbeck; Manfred Schmitt
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert review of molecular diagnostics 2010;10(7):947-62.
2010: Rudolf Napieralski; Nils Brünner; Karin Mengele; Manfred Schmitt
Emerging biomarkers in breast cancer care.
Biomarkers in medicine 2010;4(4):505-22.
2010: Nathalie Beaufort; Paulina Seweryn; Sophie de Bentzmann; Aihua Tang; Josef Kellermann; Nicolai Grebenchtchikov; Manfred Schmitt; Christian P Sommerhoff; Dominique Pidard; Viktor Magdolen
Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa.
The Biochemical journal 2010;428(3):473-82.
2010: Alexander Kreuter; A Potthoff; Norbert H Brockmeyer; Thilo Gambichler; Jochen Swoboda; Markus Stücker; Manfred Schmitt; Herbert Pfister; Ulrike Wieland
Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.
The British journal of dermatology 2010;162(6):1269-77.
2010: Manfred Schmitt; Vladimir Lazar
Cancer-related forecast biomarkers: a topic in focus of the Worldwide Innovative Network in Personalized Cancer Medicine (WIN).
Bioanalysis 2010;2(5):851-3.
2010: Nathalie Beaufort; Karolina Plaza; Daniel Utzschneider; Amelie Schwarz; Julia M Burkhart; Sabine Creutzburg; Mekdes Debela; Manfred Schmitt; Christian Ries; Viktor Magdolen
Interdependence of kallikrein-related peptidases in proteolytic networks.
Biological chemistry 2010;391(5):581-7.
2010: Lina Seiz; Matthias Kotzsch; Nicolai Grebenchtchikov; Anneke Geurts-Moespot; Susanne Fuessel; Peter Goettig; Apostolos Gkazepis; Manfred P Wirth; Manfred Schmitt; Arndt Lossnitzer; Fred C G J Sweep; Viktor Magdolen
Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.
Biological chemistry 2010;391(4):391-401.
2010: Ursula Magdolen; Manfred Schmitt; Barbara Hildebrandt; Peter Diehl; Johannes Schauwecker; Belma Saldamli; Rainer Burgkart; Jutta Tübel; Rainer Gradinger; Brigitte Royer-Pokora
Spontaneous in vitro transformation of primary human osteoblast-like cells.
Cancer genomics & proteomics 2010;7(2):61-6.
2010: K Malinowsky; C Böllner; Susanne Hipp; D Berg; Manfred Schmitt; Karl-Friedrich Becker
UPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers.
Current medicinal chemistry 2010;17(35):4370-7.
2009: Oleg Gluz; Karin Mengele; Manfred Schmitt; Ronald Kates; Raihana Diallo-Danebrock; Frauke Neff; Hans-Dieter Royer; Niels Eckstein; Svjetlana Mohrmann; Evelyn Ting; Marion Kiechle; Christopher Poremba; Ulrike Nitz; Nadia Harbeck
Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6144-51.
2009: Katja Specht; Nadia Harbeck; Jan Smida; Katja Annecke; Ulrike Reich; Joerg Naehrig; Rupert Langer; Joerg Mages; Raymonde Busch; Elisabeth Kruse; Ludger Klein-Hitpass; Manfred Schmitt; Marion Kiechle; Heinz Hoefler
Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Breast cancer research and treatment 2009;118(1):45-56.
2009: John Martens; Astrid L Margossian; Manfred Schmitt; John Foekens; Nadia Harbeck
DNA methylation as a biomarker in breast cancer.
Future oncology (London, England) 2009;5(8):1245-56.
2009: Zlatna Ruseva; Pamina Xenia Charlotte Geiger; Peter Hutzler; Matthias Kotzsch; Birgit Luber; Manfred Schmitt; Eva Gross; Ute Reuning
Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation.
Experimental cell research 2009;315(10):1759-71.
2009: Manfred Schmitt; Viktor Magdolen
Using kallikrein-related peptidases (KLK) as novel cancer biomarkers.
Thrombosis and haemostasis 2009;101(2):222-4.
2009: Michael J Duffy; R Napieralski; John Martens; P N Span; F Spyratos; F C G J Sweep; N Brunner; J A Foekens; Manfred Schmitt
Methylated genes as new cancer biomarkers.
European journal of cancer (Oxford, England : 1990) 2009;45(3):335-46.
2008: Peter Diehl; Johannes Schauwecker; Wolfram Mittelmeier; Manfred Schmitt
High hydrostatic pressure, a novel approach in orthopedic surgical oncology to disinfect bone, tendons and cartilage.
Anticancer research 2008;28(6B):3877-83.
2008: Gregor Weirich; Karin Mengele; Christina Yfanti; Apostolos Gkazepis; Daniela Hellmann; Anita Welk; Cecylia Giersig; Wen-Liang Kuo; Marsha Rich Rosner; Wei-Jen Tang; Manfred Schmitt
Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.
Biological chemistry 2008;389(11):1441-5.
2008: Nadia Harbeck; Inko Nimmrich; Arndt Hartmann; Jeffrey S Ross; Tanja Cufer; Robert Grützmann; Glen Kristiansen; angelo paradiso; Oliver Hartmann; Astrid Margossian; John Martens; Ina Schwope; Antje Lukas; Volkmar Müller; Karin Milde-Langosch; Jörg Nährig; John A Foekens; Sabine Maier; Manfred Schmitt; Ralf Lesche
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5036-42.
2008: Christina Yfanti; Karin Mengele; Apostolos Gkazepis; Gregor Weirich; Cecylia Giersig; Wen-Liang Kuo; Wei-Jen Tang; Marsha Rosner; Manfred Schmitt
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.
International journal of molecular medicine 2008;22(4):421-31.
2008: Inko Nimmrich; Anieta M Sieuwerts; Marion E Meijer-Van Gelder; Ina Schwope; Joan Bolt-de Vries; Nadia Harbeck; Thomas Koenig; Oliver Hartmann; Antje Kluth; Dimo Dietrich; Viktor Magdolen; Henk Portengen; Maxime P Look; Jan G M Klijn; Ralf Lesche; Manfred Schmitt; Sabine Maier; John A Foekens; John Martens
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Breast cancer research and treatment 2008;111(3):429-37.
2008: Hans-Joachim Stemmler; Karin Mengele; Manfred Schmitt; Nadia Harbeck; Dorit Laessig; Karin A Herrmann; Pamela Schaffer; Volker Heinemann
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Anti-cancer drugs 2008;19(8):832-6.
2008: Matthias Kotzsch; Anieta M Sieuwerts; Marianne Grosser; Axel Meye; Susanne Fuessel; Marion E Meijer-Van Gelder; Marcel Smid; Manfred Schmitt; Gustavo Baretton; Thomas Luther; Viktor Magdolen; John A Foekens
Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.
Breast cancer research and treatment 2008;111(2):229-40.
2008: Mekdes Debela; Nathalie Beaufort; Viktor Magdolen; Norman M Schechter; Charles S Craik; Manfred Schmitt; Wolfram Bode; Peter Goettig
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7.
Biological chemistry 2008;389(6):623-32.
2008: Nathalie Beaufort; Piotr Wojciechowski; Christian P Sommerhoff; Grzegorz Szmyd; Grzegorz Dubin; Sigrun Eick; Josef Kellermann; Manfred Schmitt; Jan Potempa; Viktor Magdolen
The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin.
The Biochemical journal 2008;410(1):157-65.
2008: Julia C Biermann; Leon Holzscheiter; Matthias Kotzsch; Thomas Luther; Marion Kiechle-Bahat; Fred C G J Sweep; Paul Span; Manfred Schmitt; Viktor Magdolen
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
International journal of molecular medicine 2008;21(2):251-9.
2008: Sebastian Knör; Sumito Sato; Timo Huber; Alfred Morgenstern; Frank Bruchertseifer; Manfred Schmitt; Horst Kessler; Reingard Senekowitsch-Schmidtke; Viktor Magdolen; Christof Seidl
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
European journal of nuclear medicine and molecular imaging 2008;35(1):53-64.
2007: Sabine Maier; Inko Nimmrich; Thomas Koenig; Serenella Eppenberger-Castori; Inga Bohlmann; angelo paradiso; Frédérique Spyratos; Christoph Thomssen; Volkmar Mueller; Jörg Nährig; Francesco Schittulli; Ronald Kates; Ralf Lesche; Ina Schwope; Antje Kluth; Almuth Marx; John Martens; John A Foekens; Manfred Schmitt; Nadia Harbeck
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
European journal of cancer (Oxford, England : 1990) 2007;43(11):1679-86.
2007: Lisa D Sprague; Herbert Tomaso; Karin Mengele; Daniela Schilling; Christine Bayer; Peter Stadler; Manfred Schmitt; Michael Molls
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Oncology reports 2007;17(5):1259-68.
2007: Peter Diehl; Johannes Schauwecker; Kay Eichelberg; Hans Gollwitzer; Ulla Magdolen; Ludger Gerdesmeyer; Wolfram Mittelmeier; Manfred Schmitt
Quantitative analysis of the impact of short-time high hydrostatic pressure on bone tumor-associated proteases.
International journal of molecular medicine 2007;19(4):667-73.
2007: Julia Dorn; Manfred Schmitt; Ronald Kates; Barbara Schmalfeldt; Marion Kiechle; Andreas Scorilas; Eleftherios P Diamandis; Nadia Harbeck
Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1742-8.
2007: Manfred Schmitt; Karin Mengele; Elisabeth Schueren; Fred C G J Sweep; John A Foekens; Nils Brünner; Juliane Laabs; Abha Malik; Nadia Harbeck
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers.
European journal of cancer (Oxford, England : 1990) 2007;43(5):835-44.
2007: Nadia Harbeck; Manfred Schmitt; Stefan Paepke; Heike Allgayer; Ronald Kates
Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.
Critical reviews in clinical laboratory sciences 2007;44(2):179-201.
2007: Hans-Joachim Stemmler; Manfred Schmitt; Amina Willems; Helga Bernhard; Nadia Harbeck; Volker Heinemann
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Anti-cancer drugs 2007;18(1):23-8.
2007: Razvan T Radulescu; Carla Hufnagel; Peter B Luppa; Heide Hellebrand; Wen-Liang Kuo; Marsha Rich Rosner; Nadia Harbeck; Cecylia Giersig; Alfons Meindl; Manfred Schmitt; Gregor Weirich
Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels.
International journal of oncology 2007;30(1):73-80.
2006: Julia Dorn; Nadia Harbeck; Ronald Kates; Viktor Magdolen; Linda Grass; Antoninus Soosaipillai; Barbara Schmalfeldt; Eleftherios P Diamandis; Manfred Schmitt
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Biological chemistry 2006;387(8):1121-8.
2006: Peter Diehl; Erwin Steinhauser; Hans Gollwitzer; Cornelia Heister; Johannes Schauwecker; Stefan Milz; Wolfram Mittelmeier; Manfred Schmitt
Biomechanical and immunohistochemical analysis of high hydrostatic pressure-treated Achilles tendons.
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 2006;11(4):380-5.
2006: Panagiotis Prezas; Matthias J E Arlt; Petar Viktorov; Antoninus Soosaipillai; Leon Holzscheiter; Manfred Schmitt; Maroulio Talieri; Eleftherios P Diamandis; Achim Krüger; Viktor Magdolen
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.
Biological chemistry 2006;387(6):807-11.
2006: Ulla Magdolen; Jörg Auernheimer; Claudia Dahmen; Johannes Schauwecker; Hans Gollwitzer; Jutta Tübel; Reiner Gradinger; Horst Kessler; Manfred Schmitt; Peter Diehl
Growth promoting in vitro effect of synthetic cyclic RGD-peptides on human osteoblast-like cells attached to cancellous bone.
International journal of molecular medicine 2006;17(6):1017-21.
2006: Leon Holzscheiter; Julia C Biermann; Matthias Kotzsch; Panagiotis Prezas; Juliane Farthmann; Gustavo B Baretton; Thomas Luther; Vivianne C G Tjan-Heijnen; Maroulio Talieri; Manfred Schmitt; Fred C G J Sweep; Paul Span; Viktor Magdolen
Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer.
Clinical chemistry 2006;52(6):1070-9.
2006: Hans-Joachim Stemmler; Manfred Schmitt; Nadia Harbeck; A Willems; H Bernhard; D Lässig; S Schoenberg; Volker Heinemann
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.
Oncology reports 2006;15(5):1373-7.
2006: John A Foekens; David Atkins; Yi Zhang; Fred C G J Sweep; Nadia Harbeck; angelo paradiso; Tanja Cufer; Anieta M Sieuwerts; Dmitri Talantov; Paul Span; Vivianne C G Tjan-Heijnen; Alfredo F Zito; Katja Specht; Heinz Hoefler; Rastko Golouh; Francesco Schittulli; Manfred Schmitt; Louk V A M Beex; Jan G M Klijn; Yixin Wang
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1665-71.
2006: Carla A Borgoño; Tadaaki Kishi; Andreas Scorilas; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1487-93.
2006: Nathalie Beaufort; Mekdes Debela; Sabine Creutzburg; Josef Kellermann; Wolfram Bode; Manfred Schmitt; Dominique Pidard; Viktor Magdolen
Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Biological chemistry 2006;387(2):217-22.
2006: Lisa D Sprague; Karin Mengele; Daniela Schilling; Anneke Geurts-Moespot; Fred C G J Sweep; Peter Stadler; Manfred Schmitt; Michael Molls
Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells.
Oncology 2006;71(3-4):282-91.
2006: Manfred Schmitt; Alexandra S Sturmheit; Anita Welk; Christel Schnelldorfer; Nadia Harbeck
Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
Methods in molecular medicine 2006;120():245-65.
2006: Johannes Schauwecker; Lilly Wirthmann; Manfred Schmitt; Jutta Tuebel; Ulla Magdolen; Reiner Gradinger; Wolfram Mittelmeier; Peter Diehl
Effect of extracorporeal high hydrostatic pressure on cellular outgrowth from tumor-afflicted bone.
Anticancer research 2006;26(1A):85-9.
2005: Irene Schmid; Manfred Schmitt; Monika Streiter; Rita Meilbeck; Rainer J Haas; Daniel Stachel
Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia.
European journal of medical research 2005;10(11):457-61.
2005: Matthias Kotzsch; Juliane Farthmann; Axel Meye; Susanne Fuessel; Gustavo B Baretton; Vivianne C G Tjan-Heijnen; Manfred Schmitt; Thomas Luther; Fred C G J Sweep; Viktor Magdolen; Paul Span
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(17):2760-8.
2005: Janna Krol; Karin Mengele; Irina Ottl-Mantchenko; Anita Welk; Irina Wasilewitsch; Stephanie Pildner von Steinburg; Karl-Theodor M Schneider; Manfred Schmitt
Ex vivo detection of apoptotic trophoblast cells applying flow cytofluorometry and immunocytochemistry using M30 antibody directed to the cytokeratin 18 neo-epitope.
International journal of molecular medicine 2005;16(3):415-20.
2005: Katharina Seck; Silvia Riemer; Ronald Kates; Tobias Ullrich; Verena Lutz; Nadia Harbeck; Manfred Schmitt; Marion Kiechle; Robert B Diasio; Eva Gross
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5886-92.
2005: Karin Mengele; Nadia Harbeck; Ute Reuning; Viktor Magdolen; Manfred Schmitt
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
Hämostaseologie 2005;25(3):301-10.
2005: Peter Diehl; Manfred Schmitt; Johannes Schauwecker; Kay Eichelberg; Hans Gollwitzer; Reiner Gradinger; Michael Goebel; Klaus T Preissner; Wolfram Mittelmeier; Ulla Magdolen
Effect of high hydrostatic pressure on biological properties of extracellular bone matrix proteins.
International journal of molecular medicine 2005;16(2):285-9.
2005: Nicolai Grebenchtchikov; Teresa M Maguire; R Riisbro; Anneke Geurts-Moespot; Norma O'Donovan; Manfred Schmitt; G McGreal; Enda McDermott; N O'Higgins; Nils Brünner; C G J Sweep; Michael J Duffy
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Oncology reports 2005;14(1):235-9.
2005: Brigitte Hundsdorfer; Hans-Florian Zeilhofer; Klaus Peter Bock; Peer Dettmar; Manfred Schmitt; Andreas Kolk; Christoph Pautke; Hans-Henning Horch
Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 2005;33(3):191-6.
2005: John Martens; Inko Nimmrich; Thomas Koenig; Maxime P Look; Nadia Harbeck; Fabian Model; Antje Kluth; Joan Bolt-de Vries; Anieta M Sieuwerts; Henk Portengen; Marion E Meijer-Van Gelder; Christian Piepenbrock; Alexander Olek; Heinz Höfler; Marion Kiechle; Jan G M Klijn; Manfred Schmitt; Sabine Maier; John A Foekens
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Cancer research 2005;65(10):4101-17.
2005: Florian-Dominique Naal; Karin Mengele; Johannes Schauwecker; Hans Gollwitzer; Ludger Gerdesmeyer; Ute Reuning; Wolfram Mittelmeier; Reiner Gradinger; Manfred Schmitt; Peter Diehl
High hydrostatic pressure-induced cell death in human chondrocytes and chondrosarcoma cells.
Anticancer research 2005;25(3B):1977-82.
2005: Georg Moessmer; Burkhardt Müller; Martin Kolben; Manfred Schmitt; Karl Theodor Maria Schneider; Almut Artmann
HELLP syndrome with fetal growth retardation in a woman homozygous for the prothrombin gene variant 20210A.
Thrombosis and haemostasis 2005;93(4):787-8.
2005: Buddy Setyono-Han; Jörg Stürzebecher; Wolfgang A Schmalix; Bernd Muehlenweg; Anieta M Sieuwerts; Mieke Timmermans; Viktor Magdolen; Manfred Schmitt; Jan G M Klijn; John A Foekens
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Thrombosis and haemostasis 2005;93(4):779-86.
2005: Veronika Beck; Hannes Herold; Anke Benge; Birgit Luber; Peter Hutzler; Harald Tschesche; Horst Kessler; Manfred Schmitt; Harald-Gerhard Geppert; Ute Reuning
ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
The international journal of biochemistry & cell biology 2005;37(3):590-603.
2005: Mario Del Rosso; Gabriella Fibbi; Manfred Schmitt; Paolo Mignatti
Proteases and extracellular environment.
Thrombosis and haemostasis 2005;93(2):190-1.
2004: Nadia Harbeck; Ronald Kates; Manfred Schmitt; Katja Gauger; Marion Kiechle; Fritz Janicke; Christoph Thomassen; Maxime P Look; John A Foekens
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
Clinical breast cancer 2004;5(5):348-52.
2004: Bernd Werle; Matthias Kotzsch; Tamara T Lah; Janko Kos; D Gabrijelcic-Geiger; Eberhard Spiess; J Schirren; Werner Ebert; Werner Fiehn; Thomas Luther; V Magdolen; Manfred Schmitt; N Harbeck
Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
Anticancer research 2004;24(6):4147-61.
2004: Manfred Schmitt; Nadia Harbeck; Maria Grazia Daidone; Nils Brynner; M Joe Duffy; John A Foekens; Fred C G J Sweep
Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer.
International journal of oncology 2004;25(5):1397-406.
2004: Matthias Christian Kugler; Markus Gerhard; Andreas Schnelzer; Katja Borzym; Richard Reinhardt; Manfred Schmitt; Ernst Lengyel
Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome.
Gene 2004;341():189-97.
2004: Ulla Magdolen; Florian Schroeck; Sabine Creutzburg; Manfred Schmitt; Viktor Magdolen
Non-muscle alpha-actinin-4 interacts with plasminogen activator inhibitor type-1 (PAI-1).
Biological chemistry 2004;385(9):801-8.
2004: Christian Schindlbeck; Wolfgang Janni; Naim Shabani; Brigitte Rack; Bernd Gerber; Manfred Schmitt; Nadia Harbeck; Harald Sommer; Stephan Braun; Klaus Friese
Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
Breast cancer research and treatment 2004;87(1):65-74.
2004: Eleftherios P Diamandis; Carla A Borgoño; Andreas Scorilas; Nadia Harbeck; Julia Dorn; Manfred Schmitt
Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients.
Clinical biochemistry 2004;37(9):823-9.
2004: Peter Diehl; Ute Reuning; Hans Gollwitzer; Ulla Magdolen; Ludger Gerdesmeyer; Johannes Schauwecker; Jutta Tuebel; Reiner Gradinger; Wolfram Mittelmeier; Manfred Schmitt
Effect of extracorporal high hydrostatic pressure on tumor cell adherence and viability.
Oncology reports 2004;12(2):369-73.
2004: Marion E Meijer-Van Gelder; Maxime P Look; Harry A Peters; Manfred Schmitt; Nils Brünner; Nadia Harbeck; Jan G M Klijn; John A Foekens
Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Cancer research 2004;64(13):4563-8.
2004: Maria Grazia Daidone; angelo paradiso; Massimo Gion; Nadia Harbeck; Fred Sweep; Manfred Schmitt
Biomolecular features of clinical relevance in breast cancer.
European journal of nuclear medicine and molecular imaging 2004;31 Suppl 1():S3-14.
2004: Brigitte Hundsdorfer; Hans-Florian Zeilhofer; Klaus Peter Bock; Peer Dettmar; Manfred Schmitt; Hans-Henning Horch
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
Mund-, Kiefer- und Gesichtschirurgie : MKG 2004;8(3):180-90.
2004: Brigitte Hundsdorfer; Hans-Florian Zeilhofer; Klaus Peter Bock; Peer Dettmar; Manfred Schmitt; Hans-Henning Horch
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma].
Mund-, Kiefer- und Gesichtschirurgie : MKG 2004;8(3):173-9.
2004: Peter Diehl; Bernd Hantke; Michael Hennig; Harald Tschesche; Wolfram Mittelmeier; Manfred Schmitt; Bernd Muehlenweg
Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis.
International journal of molecular medicine 2004;13(5):711-5.
2004: Nadia Harbeck; Ronald Kates; Katja Gauger; Amina Willems; Marion Kiechle; Viktor Magdolen; Manfred Schmitt
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Thrombosis and haemostasis 2004;91(3):450-6.
2004: Andreas Scorilas; Carla A Borgoño; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):678-85.
2004: R Bader; Erwin Steinhauser; Ulrich Holzwarth; Manfred Schmitt; Wolfram Mittelmeier
A novel test method for evaluation of the abrasive wear behaviour of total hip stems at the interface between implant surface and bone cement.
Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine 2004;218(4):223-30.
2003: Eva Gross; Tobias Ullrich; Katharina Seck; Volkmar Mueller; Maike de Wit; Christoph von Schilling; Alfons Meindl; Manfred Schmitt; Marion Kiechle
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Human mutation 2003;22(6):498.
2003: Fred C G J Sweep; Herbert A Fritsche; Massimo Gion; George G Klee; Manfred Schmitt
Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.
International journal of oncology 2003;23(6):1715-26.
2003: Eleftherios P Diamandis; Carla A Borgoño; Andreas Scorilas; George M Yousef; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2003;24(6):299-309.
2003: Peter Diehl; Manfred Schmitt; Gerrit Blümelhuber; Benjamin Frey; Susanne Van Laak; Steffen Fischer; Bernd Muehlenweg; Roland Meyer-Pittroff; Hans Gollwitzer; Wolfram Mittelmeier
Induction of tumor cell death by high hydrostatic pressure as a novel supporting technique in orthopedic surgery.
Oncology reports 2003;10(6):1851-5.
2003: Bernd Hantke; Nadia Harbeck; Barbara Schmalfeldt; Ingeborg Claes; Oliver Hiller; Marc-Oliver Luther; Anita Welk; Walther Kuhn; Manfred Schmitt; Harald Tschesche; Bernd Muehlenweg
Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
Biological chemistry 2003;384(8):1247-51.
2003: Ute Reuning; Viktor Magdolen; Sandra Hapke; Manfred Schmitt
Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
Biological chemistry 2003;384(8):1119-31.
2003: George M Yousef; Mary-Ellen Polymeris; Linda Grass; Antoninus Soosaipillai; Pak-Cheung Chan; Andreas Scorilas; Carla A Borgoño; Nadia Harbeck; Barbara Schmalfeldt; Julia Dorn; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Cancer research 2003;63(14):3958-65.
2003: Janna Krol; Charlotte Kopitz; Angela Kirschenhofer; Manfred Schmitt; Ulla Magdolen; Achim Krüger; Viktor Magdolen
Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
Biological chemistry 2003;384(7):1097-102.
2003: Janna Krol; Sumito Sato; Peter Rettenberger; Irmgard Assfalg-Machleidt; Manfred Schmitt; Viktor Magdolen; Ulla Magdolen
Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.
Biological chemistry 2003;384(7):1085-96.
2003: Sandra Hapke; Horst Kessler; Birgit Luber; Anke Benge; Peter Hutzler; Heinz Höfler; Manfred Schmitt; Ute Reuning
Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction.
Biological chemistry 2003;384(7):1073-83.
2003: Anne-Sofie Schrohl; Mads N Holten-Andersen; Fred Sweep; Manfred Schmitt; Nadia Harbeck; John A Foekens; Nils Brünner
Tumor markers: from laboratory to clinical utility.
Molecular & cellular proteomics : MCP 2003;2(6):378-87.
2003: Tadaaki Kishi; Linda Grass; Antoninus Soosaipillai; Andreas Scorilas; Nadia Harbeck; Barbara Schmalfeldt; Julia Dorn; Michal Mysliwiec; Manfred Schmitt; Eleftherios P Diamandis
Human kallikrein 8, a novel biomarker for ovarian carcinoma.
Cancer research 2003;63(11):2771-4.
2003: Thomas Luther; Matthias Kotzsch; Axel Meye; Thomaz Langerholc; Susanne Füssel; Natalie Olbricht; Sybille Albrecht; Detlef Ockert; Bernd Muehlenweg; Katrin Friedrich; Marianne Grosser; Manfred Schmitt; Gustavo B Baretton; Viktor Magdolen
Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
Thrombosis and haemostasis 2003;89(4):705-17.
2003: Manfred Schmitt; Viktor Magdolen; Ute Reuning
Theme Issue: update on the role of the fibrinolysis/plasminogen activation system in a cellular context.
Thrombosis and haemostasis 2003;89(4):596-8.
2003: Iris Zemzoum; Ronald Kates; Jeffrey S Ross; Peer Dettmar; Moshumi Dutta; Cordula Henrichs; Suna Yurdseven; Heinz Höfler; Marion Kiechle; Manfred Schmitt; Nadia Harbeck
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1022-8.
2003: Ute Reuning; Stefan Sperl; Charlotte Kopitz; Horst Kessler; Achim Krüger; Manfred Schmitt; Viktor Magdolen
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Current pharmaceutical design 2003;9(19):1529-43.
2003: Ronald Kates; Manfred Schmitt; Nadia Harbeck
Advanced statistical methods for the definition of new staging models.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():101-13.
2003: Frigga Roggel; Stefan Hocke; Kristina Lindemann; Sonja Sinz; Anita Welk; Martin Bosl; Martina Pabst; N Nusser; Stephan Braun; Manfred Schmitt; Nadia Harbeck
Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():89-100.
2003: Viktor Magdolen; Achim Krüger; Sumito Sato; Jutta Nagel; Stefan Sperl; Ute Reuning; Peter Rettenberger; Ulla Magdolen; Manfred Schmitt
Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():43-63.
2003: Elke Guthaus; Niko Schmiedeberg; Markus Bürgle; Viktor Magdolen; Horst Kessler; Manfred Schmitt
The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2003;162():3-14.
2002: Niko Schmiedeberg; Manfred Schmitt; Christian Rölz; Vincent Truffault; Martin Sukopp; Markus Bürgle; Olaf G Wilhelm; Wolfgang Schmalix; Viktor Magdolen; Horst Kessler
Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Journal of medicinal chemistry 2002;45(23):4984-94.
2002: Sumito Sato; Charlotte Kopitz; Wolfgang A Schmalix; Bernd Muehlenweg; Horst Kessler; Manfred Schmitt; Achim Krüger; Viktor Magdolen
High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
FEBS letters 2002;528(1-3):212-6.
2002: Nadia Harbeck; Ronald Kates; Maxime P Look; Marion E Meijer-Van Gelder; Jan G M Klijn; Achim Krüger; Marion Kiechle; Fritz Jänicke; Manfred Schmitt; John A Foekens
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Cancer research 2002;62(16):4617-22.
2002: Nadia Harbeck; Manfred Schmitt; Ronald Kates; Marion Kiechle; Iris Zemzoum; Fritz Jänicke; Christoph Thomssen
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clinical breast cancer 2002;3(3):196-200.
2002: Florian Schroeck; Nuria Arroyo De Prada; Stefan Sperl; Manfred Schmitt; Magdolen Viktor
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Biological chemistry 2002;383(7-8):1143-9.
2002: Irene Schmid; Daniel Stachel; S Freudenberg; Manfred Schmitt; Friedhelm Schuster; Rainer J Haas
Megestrol acetate to correct the nutritional status in an adolescent with growth hormone deficiency: Increase of appetite and body weight but only by increase of body water and fat mass followed by profound cortisol and testosterone depletion.
Klinische Pädiatrie 2002;214(2):54-7.
2002: Nadia Harbeck; Ronald E Kates; Manfred Schmitt
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(4):1000-7.
2002: Johannes Bange; Dieter Prechtl; Yuri Cheburkin; Katja Specht; Nadia Harbeck; Manfred Schmitt; Tatjana Knyazeva; Susanne Müller; Silvia Gärtner; Irmi Sures; Hongyang Wang; Evgeny Imyanitov; Hans-Ulrich Häring; Pjotr Knayzev; Stefano Iacobelli; Heinz Höfler; Axel Ullrich
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Cancer research 2002;62(3):840-7.
2002: Martin Janz; Nadia Harbeck; Peer Dettmar; Ursula Berger; Anja Schmidt; Karsten Jürchott; Manfred Schmitt; hans-dieter royer
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
International journal of cancer. Journal international du cancer 2002;97(3):278-82.
2002: Christian Schindlbeck; Wolfgang Janni; P Schaffer; Naim Shabani; Manfred Schmitt; Nadia Harbeck; Harald Sommer; Stephan Braun
[Tumor biology of primary breast cancer and minimal residual disease].
Acta medica Austriaca. Supplement 2002;59():27-31.
2002: Elke Guthaus; Markus Bürgle; Niko Schmiedeberg; Stefan Hocke; Alexandra Eickler; Michael D Kramer; C G J Sweep; Viktor Magdolen; Horst Kessler; Manfred Schmitt
uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Biological chemistry 2002;383(1):207-16.
2002: Mario Del Rosso; Gabriella Fibbi; Manfred Schmitt
Non-enzymatic activities of proteases: from scepticism to reality.
Biological chemistry 2002;383(1):1-4.
2002: Nuria Arroyo De Prada; Florian Schroeck; Eva-Kathrin Sinner; Bernd Muehlenweg; Jens Twellmeyer; Stefan Sperl; Olaf G Wilhelm; Manfred Schmitt; Viktor Magdolen
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
European journal of biochemistry / FEBS 2002;269(1):184-92.
2001: Manfred Schmitt
International Proteolysis Society in association with the International Conference on Protease Inhibitors--second general meeting.
IDrugs : the investigational drugs journal 2001;4(12):1361-4.
2001: Stefan Sperl; Markus Michael Mueller; Olaf G Wilhelm; Manfred Schmitt; Viktor Magdolen; Luis Moroder
The uPA/uPA receptor system as a target for tumor therapy.
Drug news & perspectives 2001;14(7):401-11.
2001: Nadia Harbeck; U Alt; U Berger; Achim Krüger; Christoph Thomssen; Fritz Jänicke; Heinz Höfler; Ronald Kates; Manfred Schmitt
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2757-64.
2001: Viktor Magdolen; Markus Bürgle; N A de Prada; Niko Schmiedeberg; C Riemer; Florian Schroeck; Josef Kellermann; Klaus Degitz; Olaf G Wilhelm; Manfred Schmitt; Horst Kessler
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Biological chemistry 2001;382(8):1197-205.
2001: Ernst Lengyel; Barbara Schmalfeldt; E Konik; K Späthe; K Härting; A Fenn; U Berger; Rafael Fridman; Manfred Schmitt; Dieter Prechtel; W Kuhn
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Gynecologic oncology 2001;82(2):291-8.
2001: Barbara Schmalfeldt; Dieter Prechtel; K Härting; K Späthe; Stephan Rutke; E Konik; Rafael Fridman; U Berger; Manfred Schmitt; W Kuhn; Ernst Lengyel
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2396-404.
2001: Sandra Hapke; Horst Kessler; Nuria Arroyo De Prada; Anke Benge; Manfred Schmitt; Ernst Lengyel; Ute Reuning
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
The Journal of biological chemistry 2001;276(28):26340-8.
2001: Bernd Muehlenweg; Stefan Sperl; Viktor Magdolen; Manfred Schmitt; N Harbeck
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Expert opinion on biological therapy 2001;1(4):683-91.
2001: Fritz Jänicke; A Prechtl; Christoph Thomssen; N Harbeck; C Meisner; M Untch; C G Sweep; H K Selbmann; Henner Graeff; Manfred Schmitt
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Journal of the National Cancer Institute 2001;93(12):913-20.
2001: Nadia Harbeck; A Krüger; S Sinz; Ronald Kates; Christoph Thomssen; Manfred Schmitt; Fritz Jänicke
Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.
Onkologie 2001;24(3):238-44.
2001: Verena Lutz; Ute Reuning; Achim Krüger; Thomas Luther; S P von Steinburg; Henner Graeff; Manfred Schmitt; Olaf G Wilhelm; Viktor Magdolen
High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Biological chemistry 2001;382(5):789-98.
2001: Sandra Hapke; M Gawaz; K Dehne; J Köhler; John FRancis Marshall; Henner Graeff; Manfred Schmitt; Ute Reuning; E Lengyel
beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.
Molecular and cellular biology 2001;21(6):2118-32.
2001: Achim Krüger; R Soeltl; I Sopov; Charlotte Kopitz; Matthias J E Arlt; Viktor Magdolen; N Harbeck; Bernd Gänsbacher; Manfred Schmitt
Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
Cancer research 2001;61(4):1272-5.
2001: Bernd Muehlenweg; A Schnelzer; B Türkmen; Ernst Lengyel; Ute Reuning; Henner Graeff; Manfred Schmitt; Viktor Magdolen
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene.
Methods in molecular medicine 2001;39():299-306.
2001: Ernst Lengyel; S Ried; M M Heiss; C Jäger; Manfred Schmitt; H Allgayer
Ras regulation of urokinase-type plasminogen activator.
Methods in enzymology 2001;333():105-16.
2000: Bernd Muehlenweg; Irmgard Assfalg-Machleidt; S G Parrado; Markus Bürgle; Sabine Creutzburg; Manfred Schmitt; Ennes A Auerswald; Werner Machleidt; Viktor Magdolen
A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
The Journal of biological chemistry 2000;275(43):33562-6.
2000: A Hannke-Lohmann; S Pildner von Steinburg; K Dehne; V Benard; Martin Kolben; Manfred Schmitt; Ernst Lengyel
Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia.
Obstetrics and gynecology 2000;96(4):582-7.
2000: Matthias Kotzsch; Thomas Luther; Nadia Harbeck; Detlef Ockert; Verena Lutz; Frank Noack; D Grossmann; Sybille Albrecht; Michael D Kramer; A Lossnitzer; Marianne Grosser; Manfred Schmitt; Viktor Magdolen
New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
International journal of oncology 2000;17(4):827-34.
2000: Peter Stadler; Horst Jürgen Feldmann; C Creighton; H F Zeilhoffer; V Zimmermann; Manfred Schmitt; Michael Molls
Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck.
The International journal of biological markers 2000;15(3):235-6.
2000: Jurgen Kowolik; W Kuhn; Jörg Nährig; Martin Werner; T Obst; Norbert Avril; Manfred Schmitt; Henner Graeff
Detection of micrometastases in sentinel lymph nodes of the breast applying monoclonal antibodies AE1/AE3 to pancytokeratins.
Oncology reports 2000;7(4):745-9.
2000: A Schnelzer; Dieter Prechtel; U Knaus; K Dehne; Markus Gerhard; Henner Graeff; Nadia Harbeck; Manfred Schmitt; Ernst Lengyel
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.
Oncogene 2000;19(26):3013-20.
2000: Ralf Hildenbrand; M Leitz; V Magdolen; T Luther; S Albrecht; Henner Graeff; HJ Stutte; Uwe Bleyl; Manfred Schmitt
Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.
Histopathology 2000;36(6):499-504.
2000: Bernd Muehlenweg; Elke Guthaus; N A de Prada; Manfred Schmitt; Niko Schmiedeberg; Matthias Kotzsch; Sabine Creutzburg; Michael D Kramer; Horst Kessler; Olaf G Wilhelm; Viktor Magdolen
Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides.
Thrombosis research 2000;98(1):73-81.
2000: Achim Krüger; R Soeltl; Verena Lutz; Olaf G Wilhelm; Viktor Magdolen; E E Rojo; P A Hantzopoulos; Henner Graeff; Bernd Gänsbacher; Manfred Schmitt
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Cancer gene therapy 2000;7(2):292-9.
2000: John A Foekens; Harry A Peters; Maxime P Look; Henk Portengen; Manfred Schmitt; Michael D Kramer; Nils Brünner; Fritz Jänicke; Marion E Meijer-Van Gelder; SC Henzen-Logmans; Wim L J van Putten; Jan G M Klijn
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Cancer research 2000;60(3):636-43.
2000: Viktor Magdolen; Nuria Arroyo De Prada; Stefan Sperl; Bernd Muehlenweg; Thomas Luther; Olaf G Wilhelm; Ulla Magdolen; Henner Graeff; Ute Reuning; Manfred Schmitt
Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator.
Advances in experimental medicine and biology 2000;477():331-41.
2000: Nadia Harbeck; Ronald Kates; K Ulm; Henner Graeff; Manfred Schmitt
Neural network analysis of follow-up data in primary breast cancer.
The International journal of biological markers 2000;15(1):116-22.
2000: Frank Noack; Manfred Schmitt; J Bauer; D Helmecke; W Krüger; Stefan Thorban; Michael Sandherr; W Kuhn; Henner Graeff; Nadia Harbeck
A new approach to phenotyping disseminated tumor cells: methodological advances and clinical implications.
The International journal of biological markers 2000;15(1):100-4.
2000: Nadia Harbeck; U Alt; U Berger; Ronald Kates; Achim Krüger; Christoph Thomssen; Fritz Jänicke; Henner Graeff; Manfred Schmitt
Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
The International journal of biological markers 2000;15(1):79-83.
2000: A Prechtl; Nadia Harbeck; Christoph Thomssen; C Meisner; M Braun; Michael Untch; M Wieland; BW Lisboa; T Cufer; Henner Graeff; K Selbmann; Manfred Schmitt; Fritz Jänicke
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.
The International journal of biological markers 2000;15(1):73-8.
1999: Frank Noack; D Helmecke; Robert Rosenberg; Stefan Thorban; Hjalmar Nekarda; U Fink; J Lewald; M Stich; K Schutze; Nadia Harbeck; Viktor Magdolen; Henner Graeff; Manfred Schmitt
CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
International journal of oncology 1999;15(4):617-23.
1999: P Della Porta; R Soeltl; H W Krell; K Collins; M O'Donoghue; Manfred Schmitt; Achim Krüger
Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Anticancer research 1999;19(5B):3809-16.
1999: Olaf G Wilhelm; S Wilhelm; G M Escott; Verena Lutz; Viktor Magdolen; Manfred Schmitt; Daniel B Rifkin; E Lynette Wilson; Henner Graeff; G Brunner
Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression.
Journal of cellular physiology 1999;180(2):225-35.
1999: S Ried; C Jäger; M Jeffers; George Vande Woude; Henner Graeff; Manfred Schmitt; Ernst Lengyel
Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor.
The Journal of biological chemistry 1999;274(23):16377-86.
1999: Nadia Harbeck; P Dettmar; Christoph Thomssen; U Berger; Kurt Ulm; Ronald Kates; Heinz Höfler; Fritz Jänicke; Henner Graeff; Manfred Schmitt
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
British journal of cancer 1999;80(3-4):419-26.
1999: W Kuhn; Barbara Schmalfeldt; Ute Reuning; L Pache; U Berger; Kurt Ulm; Nadia Harbeck; K Späthe; P Dettmar; Heinz Höfler; Fritz Jänicke; Manfred Schmitt; Henner Graeff
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
British journal of cancer 1999;79(11-12):1746-51.
1999: Nadia Harbeck; J S Ross; S Yurdseven; P Dettmar; M Pölcher; W Kuhn; Kurt Ulm; Henner Graeff; Manfred Schmitt
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
International journal of oncology 1999;14(4):663-71.
1999: Nadia Harbeck; Christoph Thomssen; U Berger; Kurt Ulm; Ronald Kates; Heinz Höfler; Fritz Jänicke; Henner Graeff; Manfred Schmitt
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Breast cancer research and treatment 1999;54(2):147-57.
1999: Manfred Schmitt; W Kuhn; N Harbeck; Henner Graeff
Thrombophilic state in breast cancer.
Seminars in thrombosis and hemostasis 1999;25(2):157-66.
1999: Ute Reuning; L Guerrini; T Nishiguchi; S Page; H Seibold; Viktor Magdolen; Henner Graeff; Manfred Schmitt
Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells.
European journal of biochemistry / FEBS 1999;259(1-2):143-8.
1998: C G J Sweep; J Geurts-Moespot; N Grebenschikov; JH de Witte; Joop J T M Heuvel; Manfred Schmitt; Michael J Duffy; Fritz Jänicke; Michael D Kramer; John A Foekens; Nils Brünner; G Brugal; A N Pedersen; Th J Benraad
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
British journal of cancer 1998;78(11):1434-41.
1998: Ute Reuning; Viktor Magdolen; Olaf G Wilhelm; K Fischer; Verena Lutz; Henner Graeff; Manfred Schmitt
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
International journal of oncology 1998;13(5):893-906.
1998: K Fischer; Verena Lutz; Olaf G Wilhelm; Manfred Schmitt; Henner Graeff; P Heiss; T Nishiguchi; Nadia Harbeck; Horst Kessler; Thomas Luther; Viktor Magdolen; Ute Reuning
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
FEBS letters 1998;438(1-2):101-5.
1998: S Wilhelm; Manfred Schmitt; J Parkinson; W Kuhn; Henner Graeff; Olaf G Wilhelm
Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc.
International journal of oncology 1998;13(4):645-51.
1998: Urs Eppenberger; Willy Kueng; J M Schlaeppi; J L Roesel; Christopher Benz; Heinz Mueller; A Matter; M Zuber; K Luescher; M Litschgi; Manfred Schmitt; John A Foekens; Serenella Eppenberger-Castori
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3129-36.
1998: Dirk J Ruiter; Cilia M Ferrier; Goos N P van Muijen; SC Henzen-Logmans; S Kennedy; Michael D Kramer; Boye Nielsen; Manfred Schmitt
Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1334-40.
1998: Ralf Hildenbrand; Wolfgang Glienke; Viktor Magdolen; Henner Graeff; HJ Stutte; Manfred Schmitt
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
Histochemistry and cell biology 1998;110(1):27-32.
1998: Hjalmar Nekarda; P Schlegel; Manfred Schmitt; M Stark; James D Mueller; Ulrich Fink; Jörg Rüdiger Siewert
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1755-63.
1998: Nadia Harbeck; P Dettmar; Christoph Thomssen; B Henselmann; W Kuhn; Kurt Ulm; Fritz Jänicke; Heinz Höfler; Henner Graeff; Manfred Schmitt
Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Anticancer research 1998;18(3C):2187-97.
1998: Christoph Thomssen; P Oppelt; Fritz Jänicke; Kurt Ulm; Nadia Harbeck; Heinz Höfler; W Kuhn; Henner Graeff; Manfred Schmitt
Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Anticancer research 1998;18(3C):2173-80.
1998: Viktor Magdolen; Sybille Albrecht; Matthias Kotzsch; C Haller; Markus Bürgle; Uwe Jacob; Marianne Grosser; Horst Kessler; Henner Graeff; M Müller; Manfred Schmitt; Thomas Luther
Immunological and functional analyses of the extracellular domain of human tissue factor.
Biological chemistry 1998;379(2):157-65.
1998: R W Stephens; N Brünner; F Jänicke; Manfred Schmitt
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
Breast cancer research and treatment 1998;52(1-3):99-111.
1997: Karl-Ludwig Laugwitz; K Kronsbein; Manfred Schmitt; K Hoffmann; Melchior Seyfarth; Albert Schömig; Martin Ungerer
Characterization and inhibition of beta-adrenergic receptor kinase in intact myocytes.
Cardiovascular research 1997;35(2):324-33.
1997: U Köhler; K Hiller; R Martin; D Langanke; G Naumann; Karl Bilek; F Jänicke; Manfred Schmitt
Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.
Gynecologic oncology 1997;66(2):268-74.
1997: Manfred Schmitt; Nadia Harbeck; Christoph Thomssen; Olaf G Wilhelm; Viktor Magdolen; Ute Reuning; Kurt Ulm; Heinz Höfler; Fritz Jänicke; Henner Graeff
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Thrombosis and haemostasis 1997;78(1):285-96.
1997: B Türkmen; Manfred Schmitt; Barbara Schmalfeldt; P Trommler; W Hell; Sabine Creutzburg; Henner Graeff; Viktor Magdolen
Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Electrophoresis 1997;18(5):686-9.
1997: Thomas Luther; Viktor Magdolen; Sybille Albrecht; M Kasper; C Riemer; Horst Kessler; Henner Graeff; M Müller; Manfred Schmitt
Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
The American journal of pathology 1997;150(4):1231-44.
1997: Markus Bürgle; M Koppitz; C Riemer; Horst Kessler; B König; U H Weidle; Josef Kellermann; F Lottspeich; Henner Graeff; Manfred Schmitt; L Goretzki; Ute Reuning; Olaf G Wilhelm; Viktor Magdolen
Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Biological chemistry 1997;378(3-4):231-7.
1997: Manfred Schmitt; Christoph Thomssen; Kurt Ulm; A Seiderer; Nadia Harbeck; Heinz Höfler; Fritz Jänicke; Henner Graeff
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
British journal of cancer 1997;76(3):306-11.
1997: P Dettmar; Nadia Harbeck; Christoph Thomssen; L Pache; P Ziffer; K Fizi; Fritz Jänicke; WB Nathrath; Manfred Schmitt; Henner Graeff; Heinz Höfler
Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.
British journal of cancer 1997;75(10):1525-33.
1997: Martin Kolben; J Bläser; K Ulm; Manfred Schmitt; K T M Schneider; H Tschesche; Henner Graeff
Angiogenin plasma levels during pregnancy.
American journal of obstetrics and gynecology 1997;176(1 Pt 1):37-41.
1996: Ilka Ott; Franz-Josef Neumann; Meinrad Gawaz; Manfred Schmitt; Albert Schömig
Increased neutrophil-platelet adhesion in patients with unstable angina.
Circulation 1996;94(6):1239-46.
1996: M Kolben; A Lopens; J Bläser; Kurt Ulm; Manfred Schmitt; K T M Schneider; H Tschesche
Proteases and their inhibitors are indicative in gestational disease.
European journal of obstetrics, gynecology, and reproductive biology 1996;68(1-2):59-65.
1996: Th J Benraad; J Geurts-Moespot; J Grøndahl-Hansen; Manfred Schmitt; Joop J T M Heuvel; JH de Witte; John A Foekens; R E Leake; Nils Brünner; C G J Sweep
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1371-81.
1996: Stephan N Wagner; Michael J Atkinson; S Thanner; Manfred Schmitt; O Wilhelm; M Rotter; Heinz Höfler
Type-1 plasminogen activator inhibitor in human renal cell carcinoma.
The Journal of pathology 1996;179(1):95-9.
1996: Viktor Magdolen; P Rettenberger; M Koppitz; L Goretzki; H Kessler; U H Weidle; B König; Henner Graeff; Manfred Schmitt; Olaf G Wilhelm
Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
European journal of biochemistry / FEBS 1996;237(3):743-51.
1996: Stephan N Wagner; Michael J Atkinson; C Wagner; Heinz Höfler; Manfred Schmitt; O Wilhelm
Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.
Histochemistry and cell biology 1996;105(1):53-60.
1995: Ute Reuning; Olaf G Wilhelm; T Nishiguchi; L Guerrini; F Blasi; Henner Graeff; Manfred Schmitt
Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
Nucleic acids research 1995;23(19):3887-93.
1995: Barbara Schmalfeldt; W Kuhn; Ute Reuning; L Pache; P Dettmar; Manfred Schmitt; Fritz Jänicke; Heinz Höfler; Henner Graeff
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Cancer research 1995;55(18):3958-63.
1995: S Triebel; J Bläser; T Gote; G Pelz; E Schüren; Manfred Schmitt; Harald Tschesche
Evidence for the tissue inhibitor of metalloproteinases-1 (TIMP-1) in human polymorphonuclear leukocytes.
European journal of biochemistry / FEBS 1995;231(3):714-9.
1995: Christoph Thomssen; Manfred Schmitt; L Goretzki; P Oppelt; L Pache; P Dettmar; Fritz Jänicke; Henner Graeff
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(7):741-6.
1995: Olaf G Wilhelm; Manfred Schmitt; S Höhl; R Senekowitsch; Henner Graeff
Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.
Clinical & experimental metastasis 1995;13(4):296-302.
1995: Stephan N Wagner; Michael J Atkinson; S Thanner; C Wagner; Manfred Schmitt; O Wilhelm; M Rotter; Heinz Höfler
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
The American journal of pathology 1995;147(1):183-92.
1995: Manfred Schmitt; Olaf G Wilhelm; Fritz Jänicke; Viktor Magdolen; Ute Reuning; H Ohi; N Moniwa; H Kobayashi; U Weidle; Henner Graeff
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Journal of obstetrics and gynaecology (Tokyo, Japan) 1995;21(2):151-65.
1995: U Magdolen; Viktor Magdolen; Manfred Schmitt; Wolfhard Bandlow
Selection of specific gene probes by combined use of low-stringency PCR amplification and Southern-blot hybridization.
Current genetics 1995;27(4):390-2.
1995: Nadia Harbeck; P Dettmar; Christoph Thomssen; L Pache; P Ziffer; K Fizi; Fritz Jänicke; W Nathrath; Manfred Schmitt; Henner Graeff
[Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma].
Gynäkologisch-geburtshilfliche Rundschau 1995;35 Suppl 1():142-7.
1994: W Kuhn; L Pache; Barbara Schmalfeldt; P Dettmar; Manfred Schmitt; Fritz Jänicke; Henner Graeff
Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Gynecologic oncology 1994;55(3 Pt 1):401-9.
1994: S Wilhelm; Olaf G Wilhelm; Manfred Schmitt; Henner Graeff
Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex.
Biological chemistry Hoppe-Seyler 1994;375(9):603-8.
1994: John A Foekens; Manfred Schmitt; Wim L J van Putten; Harry A Peters; M D Kramer; F Jänicke; Jan G M Klijn
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1648-58.
1994: H Nekarda; Manfred Schmitt; K Ulm; A Wenninger; H Vogelsang; K Becker; Jürgen D Roder; Ulrich Fink; Jörg Rüdiger Siewert
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Cancer research 1994;54(11):2900-7.
1994: Fritz Jänicke; L Pache; Manfred Schmitt; Kurt Ulm; Christoph Thomssen; A Prechtl; Henner Graeff
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Cancer research 1994;54(10):2527-30.
1994: M Kolben; A Lopens; Manfred Schmitt; K T M Schneider; Henner Graeff
[Changes in fibrinolysis-associated parameters in HELLP syndrome].
Geburtshilfe und Frauenheilkunde 1994;54(5):257-61.
1994: AJ McGahon; Reid P Bissonnette; Manfred Schmitt; K M Cotter; Douglas R Green; Thomas G Cotter
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.
Blood 1994;83(5):1179-87.
1994: Olaf G Wilhelm; U Weidle; S Höhl; P Rettenberger; Manfred Schmitt; Henner Graeff
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
FEBS letters 1994;337(2):131-4.
1994: H Nekarda; J R Siewert; Manfred Schmitt; K Ulm
Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer.
Lancet 1994;343(8889):117.
1993: Nina Pedersen; Manfred Schmitt; E Rønne; M I Nicoletti; Gunilla Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
The Journal of clinical investigation 1993;92(5):2160-7.
1993: Hiroshi Kobayashi; H Ohi; H Shinohara; Motoi Sugimura; T Fujii; Toshihiko Terao; Manfred Schmitt; L Goretzki; N Chucholowski; Fritz Jänicke
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
British journal of cancer 1993;67(3):537-44.
1993: Nadia Harbeck; E Schüren; N Yamamoto; L Pache; Manfred Schmitt; Fritz Jänicke; P Dettmar; Heinz Höfler; Henner Graeff
[DNA flow cytometric analysis in primary breast cancer. S-phase and ploidy status as prognostic factors and their correlation to tumor-associated proteolytic factors].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():303-4.
1993: Nadia Harbeck; E Schüren; N Yamamoto; Manfred Schmitt; Heinz Höfler; Henner Graeff
[Development of a technique for isolation of intact tumor cells from fresh breast or ovarian cancer tissue. Use in analysis of tumor-associated proteolytic factors].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():277-9.
1993: S Wilhelm; Olaf G Wilhelm; Manfred Schmitt; V Möbus; R Kreienberg; Henner Graeff
[Expression of the cell surface receptor for thrombin, thrombomodulin, in human ovarian cancer cells].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():202-3.
1993: Henner Graeff; Olaf G Wilhelm; Fritz Jänicke; Manfred Schmitt
[Tumor biology-oriented treatment concepts].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():193-6.
1992: Manfred Schmitt; Fritz Jänicke; N Moniwa; N Chucholowski; L Pache; Henner Graeff
Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Biological chemistry Hoppe-Seyler 1992;373(7):611-22.
1992: L Goretzki; Manfred Schmitt; K Mann; J Calvete; N Chucholowski; M Kramer; W A Günzler; Fritz Jänicke; Henner Graeff
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
FEBS letters 1992;297(1-2):112-8.
1992: N Chucholowski; Manfred Schmitt; L Goretzki; E Schüren; N Moniwa; U Weidle; M Kramer; B Wagner; Fritz Jänicke; Henner Graeff
Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
Biochemical Society transactions 1992;20(1):208-16.
1991: Fritz Jänicke; Manfred Schmitt; Henner Graeff
Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
Seminars in thrombosis and hemostasis 1991;17(3):303-12.
1991: Manfred Schmitt; N Chucholowski; E Busch; D Hellmann; B Wagner; L Goretzki; Fritz Jänicke; W A Günzler; Henner Graeff
Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells.
Seminars in thrombosis and hemostasis 1991;17(3):291-302.
1991: Hiroshi Kobayashi; Manfred Schmitt; L Goretzki; N Chucholowski; J Calvete; M Kramer; W A Günzler; Fritz Jänicke; Henner Graeff
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
The Journal of biological chemistry 1991;266(8):5147-52.
1991: Manfred Schmitt; N Kanayama; Fritz Jänicke; R Hafter; Henner Graeff
Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.
Advances in experimental medicine and biology 1991;297():111-28.
1991: Manfred Schmitt; L Goretzki; Fritz Jänicke; J Calvete; M Eulitz; Hiroshi Kobayashi; N Chucholowski; Henner Graeff
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
Biomedica biochimica acta 1991;50(4-6):731-41.
1990: Olaf G Wilhelm; R Hafter; A Henschen; Manfred Schmitt; Henner Graeff
Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
Blood 1990;75(8):1673-8.
1990: Manfred Schmitt; B Bültmann
Fluorescent chemotactic peptides as tools to identify the f-Met-Leu-Phe receptor on human granulocytes.
Biochemical Society transactions 1990;18(2):219-22.
1989: F Jänicke; Manfred Schmitt; K Ulm; W Gössner; Henner Graeff
Urokinase-type plasminogen activator antigen and early relapse in breast cancer.
Lancet 1989;2(8670):1049.
1989: Manfred Schmitt; N Kanayama; A Henschen; A Hollrieder; R Hafter; D Gulba; Fritz Jänicke; Henner Graeff
Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA).
FEBS letters 1989;255(1):83-8.
1988: Olaf G Wilhelm; R Hafter; E Coppenrath; M A Pflanz; Manfred Schmitt; R Babic; R Linke; W Gössner; Henner Graeff
Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma.
Cancer research 1988;48(12):3507-14.